Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.
U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a...
BMS and Five Prime Therapeutics to Evaluate Investigational Immunotherapies Opdivo and FPA008 in Six Tumor TypesNovember 24, 2014 4:09 pm | News | Comments
Bristol-Myers Squibb Company and Five Prime Therapeutics have entered into an exclusive clinical...
Bristol-Myers Squibb Company has announced plans to construct a new state-of-the-art, large-...
Bristol-Myers Squibb and Galecto Biotech AB have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions.
Bristol-Myers Squibb reported third-quarter profit of $721 million. The New York-based company said it had profit of 43 cents per share. Earnings, adjusted for non-recurring costs, came to 45 cents per share. The results beat Wall Street expectations.
Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® and IMBRUVICA® in Non-Hodgkin LymphomaOctober 14, 2014 8:48 am | News | Comments
The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Bristol-Myers Squibb has decided that it will not pursue FDA approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States and has therefore withdrawn its new drug application (NDA) for asunaprevir, an NS3/4A protease inhibitor.
Bristol-Myers Squibb and MD Anderson Cancer Center to Collaborate on Immuno-Oncology Focused Therapies for Leukemia and Hematologic MalignanciesOctober 6, 2014 8:10 am | News | Comments
Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo, Yervoy and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.
Bristol-Myers Squibb Company will settle $1.4B in pension obligations through the purchase of a group annuity contract from The Prudential Insurance Company of America for approximately 8,000 U.S. retirees and their beneficiaries who started receiving their monthly retirement benefit payments on or before June 1, 2014.
Bristol-Myers Squibb Company today announced plans to build a 650,000-square-foot office building on company-owned land at the intersection of Princeton Pike and Interstate 295 in Lawrenceville, New Jersey. Construction is expected to begin this fall and the new facility is expected to open by the end of 2016.
Bristol-Myers Squibb Company today announced that the European Commission has approved Daklinza (daclatasvir) for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults.
Bristol-Myers Squibb Company and Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.
Bristol-Myers Squibb Company and Celgene Corporation announced the establishment of a clinical trial collaboration to evaluate a combination regimen of Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), and Celgene’s chemotherapy ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension), in a Phase I study.
Allied Minds and Bristol-Myers Squibb Company today announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S.
European Commission Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary EmbolismJuly 29, 2014 8:38 am | News | Comments
Bristol-Myers Squibb and Pfizer announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway.
Bristol-Myers Squibb Co.'s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.
Bristol-Myers Squibb Company today announced that, following discussions with the FDA, the company is planning a third quarter submission of a Biologics Licensing Application (BLA) for Opdivo® (nivolumab) for previously treated advanced melanoma.
Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® and Sunvepra® Dual RegimenJuly 7, 2014 8:19 am | News | Comments
Bristol-Myers Squibb Company has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza® (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor ( in vitro ), and Sunvepra® (asunaprevir), a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options.
BMS Issues Voluntary Nationwide Recall of COUMADIN® for Injection Due to Presence of Particulate MatterJune 30, 2014 1:40 pm | News | Comments
Bristol-Myers Squibb Company is voluntarily recalling six lots of COUMADIN® FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company’s investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples.
Bristol-Myers said Tuesday that its skin cancer drug nivolumab worked in a late-stage clinical trial, leading the drugmaker to end the study early. Bristol-Myers said patients treated with nivolumab lived longer than patients who received only chemotherapy.
Bristol-Myers Squibb Company has announced that the U.S. Court of Appeals for the Federal Circuit has denied the company’s appeal of a February 2013 ruling by the U.S. District Court for the District of Delaware that found the patent covering Baraclude (entecavir), U.S. patent 5,206,244 invalid.
Bristol-Myers Squibb and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India.
Actavis has filed an Abbreviated New Drug Application with the FDA seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza.
Bristol-Myers Squibb Company and Incyte Corporation announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, nivolumab, and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.
Bristol-Myers Squibb and AbbVie today announced that the FDA has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies
Shares of Bristol-Myers Squibb slumped Thursday after the drugmaker reported disappointing clinical trial data for an experimental cancer treatment.
BMS and Celldex Therapeutics to Evaluate the Combination of Investigational Immunotherapies Nivolumab and VarlilumabMay 14, 2014 8:46 am | News | Comments
Bristol-Myers Squib and Celldex Therapeutics have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a Phase 1/2 study.
Bristol-Myers Squibb Company today announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company, effective July 1, 2014.
- Page 1